Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in first-line advanced ovarian cancer
2010-024305-13Phase 2Completed
- Sponsor
- Quest PharmaTech Inc.
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Quest PharmaTech Inc. Started May 2011; status: completed.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2010-024305-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024305-13.